Intravitreal aflibercept 2 mg every 8 weeks after 5 initial monthly doses (IVT-AFL 2q8) improved visual acuity outcomes in eyes with center-involved diabetic macular edema (DME) to a greater extent than intravitreal ranibizumab 0.5 mg as needed (IVR 0.5 mg PRN), though vascular endothelial growth factor (VEGF) inhibition with either IVT-AFL or IVR is efficacious and appears safe
Alcon has received European CE mark for a trifocal IOL (AcrySof IQ PanOptix) designed for patients who are undergoing cataract surgery and want to address their near, intermediate, and distance vision needs with one lens.
A laser tissue bonding apparatus integrated with an optical coherence tomography (OCT) probe is a plausible instrument that allows for temperature-controlled laser bonding of incisions in the cornea, according to Israeli researchers. The OCT probe can provide real-time feedback of structural change of the corneal tissue, and indicate the progress and end point of the bonding.
A protein called PKal (plasma kallikrein) and its associated molecules are key players in an inflammatory molecular pathway involved in diabetic macular edema, according to a study published in Diabetes.
This follow-up study found anterior capsule opacification development and anterior capsule retraction to be more frequent 3 years after cataract surgery when an IOL with interrupted sharp optic edge at the optic–haptic junction is implanted, compared with an IOL with a continuous edge.
In this article, Dr Tanna discusses treatment options for glaucoma patients who do not show satisfactory response to a PGA while taking into consideration the two key therapeutic choice factors: IOP-lowering efficacy and tolerability.
An interventional trial recently compared standard and navigated pattern PRP techniques. In this article, Dr Kozak explains how continuous prepositioning and stabilisation of the aiming beam with navigated PRP, enables pattern application of the more effective longer pulse durations while reducing treatment times and broadens therapeutic options in proliferative diabetic retinopathy.